Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials

2003 ◽  
Vol 146 (5) ◽  
pp. 848-853 ◽  
Author(s):  
Steven Joseph Haas ◽  
Theo Vos ◽  
Richard E Gilbert ◽  
Henry Krum
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Clinical Trials ◽  
Chronic Heart Failure ◽  
Large Scale ◽  
Meta Analysis ◽  
Patients With Diabetes ◽  
Β Blockers

A Review of Carvedilol Arrhythmia Data in Clinical Trials

2005 ◽  
Vol 10 (4_suppl) ◽  
pp. S59-S68 ◽  
Author(s):  
Peter R. Kowey
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Clinical Trials ◽  
Sudden Death ◽  
Large Scale ◽  
Left Ventricular ◽  
Antiarrhythmic Agents ◽  
Adrenergic Blockade ◽  
Variable Effect ◽  
Β Blockers

β-Blockers are currently being evaluated more intensively to define their role in clinical use as antiarrhythmic agents. β-Adrenergic blockade has been studied in relation to atrial fibrillation, ventricular arrhythmias, and sudden death; however, it is apparent from a number of studies that not all β-blockers are equally effective. Randomized clinical trial data, both in heart failure and post-myocardial infarction (MI) patients, have shown differences in mortality benefits in addition to a variable effect on arrhythmias and sudden death. Carvedilol, a third-generation β-blocker with proven clinical benefit in the management of heart failure and post-MI patients, has properties that may make it an effective antiarrhythmic agent. This paper reviews the current clinical arrhythmia data available for carvedilol from large-scale clinical trials and small studies. The trial evidence demonstrates that carvedilol therapy can be an effective adjunctive rate-control therapy in patients with atrial fibrillation, prevent mortality in patients with heart failure or post-MI with left ventricular dysfunction, with or without atrial fibrillation, and reduce its onset and the incidence of ventricular arrhythmia and sudden death.

PS110 GSTM1 Null Genotype Isn’t Associated With Increased Risk of Chronic Heart Failure Among Patients With Diabetes Mellitus

Global Heart ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e33
Author(s):  
N. Jankovic ◽  
D.V. Simic ◽  
S. Radovanovic ◽  
O. Gudelj ◽  
S. Suvakov ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Gstm1 Null Genotype ◽  
Increased Risk ◽  
Patients With Diabetes

scholarly journals e0610 The Changes of B-type natriuretic peptide in chronic heart failure patients with diabetes mellitus

Heart ◽  
2010 ◽  
Vol 96 (Suppl 3) ◽  
pp. A188-A188
Author(s):  
Q. Peng ◽  
H. Su ◽  
T. Xie ◽  
D.-z. Hong ◽  
Q.-h. Wu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Heart Failure Patients ◽  
Patients With Diabetes
Sign in / Sign up

Export Citation Format

Share Document